Real-world lung cancer screening decision-making: barriers and facilitators

Lung cancer is the second most common cancer in the US and the leading cause of cancer death [1]. Following the results of the National Lung Screening Trial (NLST), which showed a 20% relative reduction in lung cancer mortality with annual low dose computed tomography (LDCT) [2], several professional societies have recommended annual LDCT screening for high-risk individuals meeting age and pack-year criteria [3 –6]. Since implementation of this recommendation, screening uptake in the US has been low and variable, with screening rates of 4%-6% among high-risk smokers [7–10].

Source: Lung Cancer - April 30, 2019 Category: Cancer & Oncology Authors: Margaret Lowenstein, Maya Vijayaraghavan, Nancy J. Burke, Leah Karliner, Sunny Wang, Melissa Peters, Amy Lozano, Celia P. Kaplan Source Type: research